Envista (NYSE:NVST – Get Free Report) had its price objective cut by research analysts at Piper Sandler from $28.00 to $26.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price target suggests a potential upside of 14.30% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Friday, September 18th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Envista in a research note on Thursday, September 3rd. JPMorgan Chase & Co. upgraded shares of Envista from a “neutral” rating to an “overweight” rating and upped their price target for the company from $29.00 to $32.00 in a research report on Thursday, September 3rd. Robert W. Baird set a $34.00 price objective on Envista in a report on Thursday, August 6th. Finally, Barclays lowered their target price on Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, June 11th. Seven research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $29.64.
View Our Latest Research Report on Envista
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $730.50 million during the quarter, compared to analysts’ expectations of $716.11 million. Envista had a return on equity of 7.88% and a net margin of 3.33%.The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.26 EPS. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, research analysts expect that Envista will post 1.53 earnings per share for the current year.
Insiders Place Their Bets
In other Envista news, SVP Mischa Reis sold 8,000 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. This represents a 22.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is owned by insiders.
Hedge Funds Weigh In On Envista
Several hedge funds and other institutional investors have recently modified their holdings of NVST. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Envista during the 2nd quarter valued at about $25,000. Nykredit A S bought a new stake in shares of Envista in the 2nd quarter worth approximately $52,000. C M Bidwell & Associates Ltd. purchased a new position in shares of Envista during the second quarter valued at approximately $63,000. Elevation Wealth Partners LLC increased its stake in shares of Envista by 262.9% during the third quarter. Elevation Wealth Partners LLC now owns 2,406 shares of the company’s stock valued at $56,000 after buying an additional 1,743 shares during the period. Finally, Parkside Financial Bank & Trust raised its holdings in shares of Envista by 246.2% during the second quarter. Parkside Financial Bank & Trust now owns 3,071 shares of the company’s stock valued at $81,000 after acquiring an additional 2,184 shares in the last quarter.
Envista Company Profile
Envista Holdings Corporation (NYSE: NVST) is a global dental-products and technologies company that develops, manufactures and markets equipment, consumables and digital solutions for dental professionals, laboratories and specialists. Its offerings support diagnosis, treatment planning, restorative dentistry, orthodontics, implant dentistry and related clinical procedures.
The company’s portfolio includes dental imaging systems and software, treatment units, handpieces, infection-control products, restorative materials, endodontic products, orthodontic brackets and aligners, dental implants, prosthetic components and laboratory solutions.
See Also
- Five stocks we like better than Envista
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
